Drug Profile
Relmacabtagene autoleucel - JW Therapeutics
Alternative Names: Carteyva; JWCAR-029; relma-celLatest Information Update: 12 Mar 2024
Price :
$50
*
At a glance
- Originator Juno Therapeutics
- Developer JW Therapeutics; Shanghai Ming Ju Biotechnology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Follicular lymphoma; Non-Hodgkin's lymphoma
- Preregistration Diffuse large B cell lymphoma; Mantle-cell lymphoma
- Phase I Chronic lymphocytic leukaemia; Precursor B-cell lymphoblastic leukaemia-lymphoma; Systemic lupus erythematosus
Most Recent Events
- 07 Mar 2024 Shanghai Ming Ju Biotechnology plans a phase I trial for Systemic Lupus Erythematosus (Treatment-experienced) (NCT06297408)
- 04 Jan 2024 Preregistration for Mantle-cell lymphoma (Second-line therapy or greater) in China (IV)
- 04 Jan 2024 National Medical Products Administration (NMPA) of China accepts sBLA for Relmacabtagene autoleucel for Mantle cell lymphoma (Second-line therapy or greater) for review